Αρχική World News Efficacy of Taletrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC World News Efficacy of Taletrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC Από Ogkologos - 18 Απριλίου, 2025 1004 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an integrated analysis of the pivotal phase II regional TRUST-I and global TRUST-II studies Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR New Study Finds Dogs Can Sniff Out Lung Cancer — And... 10 Απριλίου, 2019 Metronomic Capecitabine as Adjuvant Therapy Provides Compelling Evidence In Locoregionally Advanced... 14 Ιουνίου, 2021 Strangers Buy Boy Stuffed Animals For His Birthday When His Mom... 25 Αυγούστου, 2021 Trial Should Change Care for AIDS-Related Kaposi Sarcoma in Sub-Saharan Africa 10 Μαρτίου, 2020 Φόρτωση περισσοτέρων HOT NEWS Consensus on Conceptual Framework for Precision Cancer Medicine in Germany For People with Inherited Risk of Stomach Cancer, Gastrectomy Has Lasting... FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for... AI-Supported Mammography Screening Shows Favourable Outcomes Compared with Standard Double Reading